Trials / Completed
CompletedNCT03155087
PRKAA2 Genetic Polymorphisms and Its Susceptibility to Chinese Type 2 Diabetes Mellitus and Diabetic Nephropathy
The Influence of AMPK Subunit Alpha (PRKAA2) Genetic Polymorphisms With Susceptibility to Chinese Type 2 Diabetes Mellitus and Diabetic Nephropathy
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 750 (actual)
- Sponsor
- People's Hospital of Zhengzhou University · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Accepted
Summary
Metformin is a classical oral antidiabetic drug, often recommended to be the first-choice treatment of type 2 diabetes mellitus (T2DM). Based on the previous research on PRKAA2, STK11 and diabetes, this study aimed to investigate the distributive characteristic of PRKAA2 and STK11 polymorphisms and the potential influence of STK11polymorphisms on metformin efficacy among Chinese T2DM patients, discuss the association of PRKAA2 polymorphisms between T2DM patients and healthy subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Metformin |
Timeline
- Start date
- 2013-06-01
- Primary completion
- 2015-06-01
- Completion
- 2015-12-01
- First posted
- 2017-05-16
- Last updated
- 2017-05-16
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03155087. Inclusion in this directory is not an endorsement.